Scaling up worldwide disease surveillance and vaccine production is an expensive endeavor. Who is responsible for funding these efforts, and how are these costs distributed among all of those likely to benefit?
- Should the expected financial contribution be based upon ability to pay, likelihood of benefit, or by some other measure?
- Are developed nations morally obligated to providing assistance to developing countries lacking the financial, structural, or intellectual capacity to stage a meaningful response?
To see the spreadsheet that captured the data from this session’s online surveys, Session I report back.
Dr. Anthony So discussed how intellectual property rights heavily influence access to drugs. Normally, patents are suppose to provide assurance, but oftentimes the strategic use of intellectual property rights leads to tension between parties about sharing of information.
What are your thoughts concerning the debate about developing a cure to a pandemic (like SARS): should the cure be a public good or a private good?
What are the challenges to sharing information in the global arena?
Recent Comments